T1	p 107 145	vomiting after breast cancer surgery :
T2	p 218 237	Japanese patients .
T3	p 249 262	Breast cancer
T4	p 290 297	patient
T5	p 304 311	general
T6	p 449 487	patients who undergo mastectomy ( with
T7	p 654 684	women who undergo mastectomy .
T8	p 881 925	breast cancer surgery in Japanese patients .
T9	p 1011 1025	Japanese women
T10	p 1691 1822	total of 100 women ( mean [ SD ] age , 52 [ 7 ] years ; height , 154 [ 6 ] cm ; weight , 54 [ 7 ] kg ) were included in the study .
T11	p 1834 1863	group comprised 25 patients .
T12	p 2753 2805	Japanese women who underwent breast cancer surgery .
T13	i 20 62	propofol , droperidol , and metoclopramide
T14	i 190 208	placebo-controlled
T15	i 304 322	general anesthesia
T16	i 556 564	propofol
T17	i 624 631	placebo
T18	i 754 846	subhypnotic dose of propofol with the conventional antiemetics droperidol and metoclopramide
T19	i 984 1002	placebo-controlled
T20	i 1070 1299	IV administration of propofol 0.5 mg/kg , droperidol 20 microg/kg , metoclopramide 0.2 mg/kg , or placebo ( isotonic saline ) immediately after skin suture . A standard general anesthetic technique , including sevoflurane and air
T21	i 2070 2078	propofol
T22	i 2105 2115	droperidol
T23	i 2146 2160	metoclopramide
T24	i 2188 2195	placebo
T25	i 2325 2335	droperidol
T26	i 2342 2350	propofol
T27	i 2355 2365	droperidol
T28	i 2441 2455	metoclopramide
T29	i 2643 2651	propofol
T30	i 2666 2689	droperidol 20 microg/kg
T31	i 2860 2868	propofol
T32	i 2873 2883	droperidol
T33	i 2898 2936	metoclopramide 0.2 mg/kg and placebo .
T34	o 96 115	nausea and vomiting
T35	o 393 399	nausea
T36	o 404 412	vomiting
T37	o 740 748	efficacy
T38	o 1280 1299	sevoflurane and air
T39	o 1303 1309	oxygen
T40	o 1339 1343	PONV
T41	o 1549 1574	extrapyramidal symptoms .
T42	o 1942 2025	patient demographics , surgery type , or awakening time . The prevalences of PONV 0
T43	o 2240 2258	prevalence of PONV
T44	o 2407 2426	prevalences of PONV
T45	o 2501 2524	Extrapyramidal symptoms
T46	o 2597 2601	PONV
T47	o 2825 2829	PONV